Molbio Diagnostics IPO
IPO GMP
+₹116
+14% expected gain
Price Band
₹768 - ₹807
Lot Size
18 shares
Min Investment
₹14,526
Listing Date
August 17, 2026
IPO Details
Subscription Status
How many times each investor category has bid for the issue.
Strengths & Risks
Strengths
- Strong Position in Molecular Diagnostics: Favorably placed to take advantage of the emerging molecular diagnostics market owing to its Truenat point-of-care diagnostics platform.
- Innovation & R&D Capability: Good innovation and research & development capacity demonstrated by past successful development of innovative diagnostic products.
- Innovative Point-of-Care Platform: Has developed and commercialized its proprietary Truenat point-of-care molecular diagnostics platform based on PCR.
Risks
- R&D & Regulatory Approval Risk: The company is dependent on effective research and development and regulatory approval of new diagnostic tests.
- Variable Sales Demand: Variable sales cycle makes it difficult to predict revenues and performance of the company.
- Demand Forecasting & Stock Management Risk: The inability to forecast and manage inventories correctly may result in excessive inventory or shortage thereof.
Financials
Restated summary financials for the most recent periods.
Figures are indicative and restated for presentation.
Molbio Diagnostics IPO Review
Analysis based on live GMP, subscription, and issue details.
As of today, Molbio Diagnostics IPO is trading at a grey market premium (GMP) of +₹116 (+14% estimated listing gain), indicating positive market sentiment.
The IPO has been subscribed 70.26x overall — QIB: 186.39x, NII: 49.8x, Retail: 12.96x.
Molbio Diagnostics IPO subscription has closed. The shares are expected to list on August 17, 2026.
The minimum investment required is ₹14,526 for 18 shares (1 lot). Retail investors can apply at cut-off price for the best chance of allotment.
Key strengths include: Strong Position in Molecular Diagnostics: Favorably placed to take advantage of the emerging molecular diagnostics market owing to its Truenat point-of-care diagnostics platform.; Innovation & R&D Capability: Good innovation and research & development capacity demonstrated by past successful development of innovative diagnostic products.. Investors should note the following risks: R&D & Regulatory Approval Risk: The company is dependent on effective research and development and regulatory approval of new diagnostic tests.; Variable Sales Demand: Variable sales cycle makes it difficult to predict revenues and performance of the company..
Disclaimer: IPO GMP is indicative and sourced from the grey market. This is not investment advice. Please consult a SEBI-registered advisor before investing.
Molbio Diagnostics IPO — Frequently Asked Questions
What is Molbio Diagnostics IPO GMP today?
Molbio Diagnostics IPO GMP (grey market premium) today is +₹116, suggesting an estimated listing gain of +14%. GMP is indicative and subject to change.
What is the price band of Molbio Diagnostics IPO?
The price band for Molbio Diagnostics IPO is ₹768 - ₹807 with a lot size of 18 shares. The minimum investment required is ₹14,526.
When is Molbio Diagnostics IPO allotment date?
Molbio Diagnostics IPO allotment is expected to be finalised on August 13, 2026. You can check your allotment status on the registrar's website (Kfin Technologies Ltd.) using your PAN number.
When will Molbio Diagnostics IPO list on NSE/BSE?
Molbio Diagnostics IPO is expected to list on BSE, NSE on August 17, 2026.
How to check Molbio Diagnostics IPO allotment status?
To check Molbio Diagnostics IPO allotment status, visit the registrar's website (Kfin Technologies Ltd.) and enter your PAN number, application number, or DP/Client ID. You can also check on the BSE IPO allotment page at https://www.bseindia.com/investors/appli_check.aspx.
Should I apply for Molbio Diagnostics IPO?
Molbio Diagnostics IPO is showing a strong GMP of +₹116 (+14%), indicating positive market sentiment for listing gains. However, GMP is informal and not a guarantee of returns. Evaluate the company's fundamentals, price band, and your own risk appetite before applying. IPOLyst is not a SEBI-registered investment advisor — please do your own research.
What is the lot size of Molbio Diagnostics IPO?
The lot size for Molbio Diagnostics IPO is 18 shares per lot. The minimum investment for retail investors is ₹14,526. Retail investors can apply for a maximum of 13 lots or up to ₹2 lakh, whichever is lower.